Clinical Trials Logo

Renal Insufficiency, Chronic clinical trials

View clinical trials related to Renal Insufficiency, Chronic.

Filter by:

NCT ID: NCT01742585 Completed - Clinical trials for Chronic Kidney Disease

A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Start date: October 2012
Phase: Phase 3
Study type: Interventional

This is a randomized, double blind, placebo-controlled multi-center study to examine the efficacy and safety of ASP1585 in chronic kidney disease patients with hyperphosphatemia not on dialysis.

NCT ID: NCT01739660 Completed - Clinical trials for Chronic Kidney Disease Stage 5

Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis

Start date: December 2012
Phase: Phase 1
Study type: Interventional

This is a Phase 1 single dose study conducted to evaluate the PK and PD of pegloticase administered to hemodialysis patients. A single dose of pegloticase will be administered intravenously to male or female hemodialysis patients (N = 12) starting 3 hour prior to dialysis. The study consists of a Screening Period, a Treatment Period, and Follow up Period.

NCT ID: NCT01736397 Completed - Clinical trials for Iron Deficiency Anemia

Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

Start date: November 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if KRX-0502 (ferric citrate) is a safe and effective treatment for the management of serum phosphorus levels and iron deficiency in anemic chronic kidney disease (CKD) stage 3-5 subjects not on dialysis. Total length of treatment is approximately 12 weeks.

NCT ID: NCT01736150 Completed - Clinical trials for Chronic Kidney Disease

Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis

Start date: March 2010
Phase: Phase 3
Study type: Interventional

The study aims to evaluate the efficacy and safety of sevelamer carbonate in reducing serum phosphorus and serum lipids (total and LDL-cholesterol) in Chronic Kidney Disease Patients on dialysis.

NCT ID: NCT01735773 Completed - Inflammation Clinical Trials

Role of Prohepcidin in Uremic Patients

Start date: January 2010
Phase: N/A
Study type: Observational

The investigators aimed to study the effect of prohepcidin levels on hematologic parameters and inflammatory markers in non-diabetic uremic patients. The investigators selected three groups of patients: Hemodialysis group, peritoneal dialysis group and the group with stage 4 chronic kidney disease. A control group was formed from healthy volunteers also. Each group has been planned to be formed of about 25 patients. Diabetic patients were excluded. Prohepcidin, hsCRP, IL-6, fibrinogen have been planned to be studied besides other routine biochemical analysis including hematological ones.

NCT ID: NCT01717989 Completed - Clinical trials for Chronic Kidney Disease

Study to Evaluate the Prospective Payment System

STEPPS™
Start date: June 2010
Phase: N/A
Study type: Observational

To describe trends in treatment patterns of Small Dialysis Organizations (SDOs) prior to and during the implementation of the Centers for Medicare and Medicaid Services' (CMS') policy [End Stage Renal Disease (ESRD) Prospective Payment System (PPS)] to bundle reimbursement for all dialysis services. Specifically, to describe CMS ESRD PPS quality performance measures for dialysis centers over time.

NCT ID: NCT01717248 Completed - Clinical trials for Chronic Kidney Disease

Safety Study of GCS-100 to Treat Chronic Kidney Disease

Start date: January 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of GCS-100 as a treatment for chronic kidney disease.

NCT ID: NCT01711853 Completed - Clinical trials for Renal Insufficiency, Chronic

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.

Start date: October 2012
Phase: Phase 1
Study type: Interventional

The study to be conducted is a prospective, open label trial. It is designed to evaluate the pharmacokinetic/pharmacodynamic and coagulation parameters and safety of dabigatran etexilate in patients with chronic kidney disease.

NCT ID: NCT01704079 Completed - Clinical trials for Chronic Kidney Disease

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

Start date: November 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated

NCT ID: NCT01703234 Completed - Clinical trials for Chronic Kidney Disease

FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients

Start date: January 2008
Phase: Phase 4
Study type: Interventional

There is no data about the effects of Renin angiotensin system blockage (RAS) on FGF23 and ADMA levels in diabetic patients with proteinuria. The aim of this study was to find out whether the beneficial effects of RAS blockage in diabetic proteinuria has any relation with the alteration of ADMA and FGF-23 levels. We searched for the effects of ACE inhibitor ramipril on the clinical and laboratory parameters of diabetic patients with proteinuria.